System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 42905748 DOI: 10.1158/1078-0432.CCR-26-2812

Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trial.

Clin Cancer Res

Authors: Candice Francheska B Tambaoan, Letuan Phan, Sophie Cousin, Sylvestre Le Moulec, Thomas Grellety, Sophie Schneider, Marielle Sabatini, Laura Leroy, Mathilde Cabart, Yechan Laizet, Isabelle Soubeyran, Melissa Alame, Laura Blouin, Fabienne Gerson, Emmanuel Khalifa, Russell Madison, Giuseppe Di Caro, Amaya Gasco, Merrida Childress, Noemie Huchet, Marina Pulido, Amandine Crombé, Antoine Italiano

Affiliations

  • Foundation Medicine (United States) Boston, MA United States.
  • BoRdeaux Institute of onCology Paris France.
  • Institut Bergonié Bordeaux France.
  • Clinique Marzet France.
  • Centre Hospitalier de la Côte Basque France.
  • Centre Hospitalier de la Côte Basque Bayonne France.
  • Institut Bergonié France.
  • Foundation Medicine (United States) United States.
  • Université de Bordeaux Bordeaux France.
  • Institut Bergonié Villejuif France.

Abstract

PURPOSE

COPE evaluated serial circulating tumor DNA (ctDNA) profiling with molecular tumor board (MTB) review during first-line therapy for advanced non-small cell lung cancer (NSCLC).

EXPERIMENTAL DESIGN

COPE was a multicenter, randomized (2:1), noncomparative phase II trial. Arm A underwent serial plasma profiling with every report reviewed at a weekly virtual MTB; Arm B received standard management. The primary endpoint was 18-month overall survival (OS) in Arm A versus a prespecified 40% historical benchmark; no between-arm comparison was planned.

RESULTS

Among 176 patients, 117 were assigned to Arm A and 59 to Arm B. Eighteen-month OS was 53.8% (95% CI, 44.3-62.5) and 65.7% (95% CI, 52.0-76.3), respectively. Baseline plasma profiling provided contributory information in 32 of 35 patients with noncontributory or unavailable tissue, increasing genotyping success from 69% to 97%. Paired baseline and early on-treatment samples were available in 90 patients (median, 21 days; range, 19-64). ctDNA clearance was associated with higher objective response rate (83% vs. 52%), longer progression-free survival (22.9 vs. 5.4 months; P<0.001), and longer OS (not reached vs. 17.1 months; P=0.004) than persistent detection.

CONCLUSIONS

Serial ctDNA profiling with weekly MTB review was operationally feasible and complemented tissue genotyping. Clinical benefit was not demonstrated; early ctDNA kinetics require validation in interventional trials.

MeSH

Neoplasms, Carcinoma, Non-Small-Cell Lung, Therapeutics, Tissues, Plasma